Research programme: antifibrotics - Pliant Therapeutics

Drug Profile

Research programme: antifibrotics - Pliant Therapeutics

Alternative Names: PLN-74809

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pliant Therapeutics
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Emt protein-tyrosine kinase modulators; Integrin-alphavbeta1-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrosis

Most Recent Events

  • 06 Aug 2018 Research programme: antifibrotics - Pliant Therapeutics receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
  • 06 Aug 2018 Pliant Therapeutics plans a first-in-human clinical trial for Idiopathic pulmonary fibrosis in early 2019
  • 06 Aug 2018 Pliant Therapeutics plans a clinical trial for Primary sclerosing cholangitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top